Informed-money record
SGMT · Sagimet Biosciences Inc.
Disclosed informed-money activity on this name over the last 12 months — corporate insiders, institutions, and members of Congress, from public-domain SEC and congressional filings. A dated factual record with receipts; interpretation is yours.
Bullish filings
0
Bearish filings
11
Named actors
6
Disclosed $ (bull / bear)
$0 / $1.5M
Recent disclosures
11 of 11 in the window · linked to source| Date | Who | What | Disclosed $ | Receipt |
|---|---|---|---|---|
| 2026-04-28 | Issuer (share issuance) | priced an offering | — | SEC ↗ |
| 2026-02-10 | Chief Legal & Admin. Officer Rozek Elizabeth | sold | $14K | SEC ↗ |
| 2026-02-10 | Chief Medical Officer Martins Eduardo Bruno | sold | $20K | SEC ↗ |
| 2026-02-10 | Chief Financial Officer Chauche Thierry | sold | $7K | SEC ↗ |
| 2026-02-10 | President & CEO Happel David | sold | $65K | SEC ↗ |
| 2025-11-20 | Executive Chairman Kemble George | sold | $290K | SEC ↗ |
| 2025-11-20 | Director (via Morgan Stanley Smith Barney LLC Executive Financial Services) GEORGE KEMBLE | filed notice to sell | $296K | SEC ↗ |
| 2025-08-21 | Chairman of the Board George Kemble | adopted a selling plan | — | SEC ↗ |
| 2025-07-21 | General Counsel and CCO Rozek Elizabeth | sold | $98K | SEC ↗ |
| 2025-07-21 | Chief Medical Officer Martins Eduardo Bruno | sold | $76K | SEC ↗ |
| 2025-07-21 | President & CEO Happel David | sold | $598K | SEC ↗ |
Want the read, not just the record?
Members see how notable each move is, whether the actor's track record validates, cross-source convergence, and alerts on this name.
Create a free account →Dispute or correct this record
Events dated by when the activity occurred (a trade's transaction date; a notice, stake, or announcement at its filing date); the linked filing is the authoritative record. Directional public-domain disclosures only. Descriptive, not investment advice. Methodology · Today's notable signals